Document is current
Any future updates will be listed below
-
Authors
Lescoat, Alain http://orcid.org/0000-0003-2081-8558
Roofeh, David
Kuwana, Masataka
Lafyatis, Robert
Allanore, Yannick
Khanna, Dinesh
-
Funding
Funding for this research was provided by:
national institute of arthritis and musculoskeletal and skin diseases (K24-AR063120 and R01- AR-070470, T32-AR007080, NIH/NIAMS P50 AR060780)
university hospitals hugo hôpitaux universitaires du grand ouest (AAP JCM2020)
- License Information
-
More Information
Article History
Accepted: 24 August 2021
First Online: 1 September 2021
Declarations
:
: Not applicable.
: Not applicable.
: Not applicable.
: AL: Nothing to disclose. DR: Nothing to disclose. MK: Grant support from Boehringer-Ingelheim, Ono Pharmaceuticals, Consultant: AbbVie, Boehringer-Ingelheim, Corbus, Mochida, Kissei, Galapagos NV, Speaker bureau: Asahi Kasei Pharma, Astellas, Boehringer-Ingelheim, Chugai. GSK, Janssen. Mitsubishi-Tanabe, Nippon Shinyaku. RL: has served as a consultant for Pfizer, Bristol Myers Squibb, Boehringer-Ingleheim, Formation, Sanofi, Boehringer-Mannheim, Merck and Genentech/Roche; holds or recently had research grants from Corbus, Formation, Moderna, Regeneron, Pfizer and Kiniksa and holds equity in Thirona Bio. YA: Grant support from Alpine ImmunoSciences, Roche and Sanofi. Consultant: Bayer, Boehringer Ingelheim, Genentech/Roche, Medsenic, Sanofi-Aventis. DK: Grant support from NIH, Immune Tolerance Network, Bayer, BMS, Horizon, Pfizer. Consultant: Acceleron, Actelion, Abbvie, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, Corbus, Gilead, Galapagos, Genentech/Roche, GSK, Horizon, Merck, Mitsubishi Tanabe Pharma, Sanofi-Aventis, and United Therapeutics. Stocks: Eicos Sciences, Inc (less than 5%). Leadership/Equity position – Chief Medical Officer, CiviBioPharma/Eicos Sciences, Inc.
